Drug intelligence / Profile preview

setrobuvir

Development stage: Phase 2
Lead developer: Roche
Modality: Small Molecules
Administration: Oral

Overview

Setrobuvir is an orally administered, small-molecule non-nucleoside inhibitor of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase. It was developed as a direct acting antiviral for the treatment of chronic hepatitis C infection, specifically targeting genotype 1. Setrobuvir was discovered by Anadys Pharmaceuticals and later acquired by Roche, which terminated its development in July 2015 after Phase II clinical trials. The drug demonstrated potency and specificity against HCV genotype 1 NS5B polymerase and was studied in combination with pegylated interferon and ribavirin, as well as in interferon-free regimens with other direct acting antivirals[1][2][4][7].

Other names: setrobuvir

Targets

NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)

Beyond the preview

Go deeper on setrobuvir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on setrobuvir.

Explore the full profile